Idea Description
Supplementary Information
Innovation 'Elevator Pitch':
We design and develop devices that interface with the brain & CNS including wearable, implantable and surgical brain mapping devices. These devices are wireless and low profile and use Blue Tooth for uploading recordings to the cloud.
Overview of Innovation:
Our innovation is in our unique business proposition and our expertise in neurosciences technology. We do not have off the shelf medical devices that we try to sell to you. Our business model is to provide a technology platform for scientists, researchers, clinicians and entrepreneurs to develop their own ideas and develop their own devices with their IP. We are your outsourced product development, prototyping, R & D and regulatory partner so you can get your idea to market much quicker and without the need to juggle multiple suppliers.
Stage of Development:
Evaluation stage - Representative model or prototype system developed and can be effectively evaluated
Similar Content3
Innovation 'Elevator Pitch':
Medopad's remote monitoring platform provides clinicians with insight into patient progress in between clinic appointments. This can prevent unncessary outpatient appointments or bring forward appointments for patients who are not progressing well. 
Overview of Innovation:
The Medopad app is a health ecosystem with a patient view and a clinician view. It is very intuitive and user-friendly, having been designed with Apple in their Cupertino, California labs. 

Patient app
Patients interact with Medopad through a single smartphone app or via connected devices and sensors. Instead of multiple apps for each disease, patients have a single, centralised point of access via the Medopad platform. The Medopad app is composed of different modules and divided into four user-friendly and intuitive sections: patient profile, data collection, patient dashboard, and learning & education. Medopad provides 100+ data collection modules ranging in functionality: medication and symptom trackers, photo and video capture, tele-consultation, and questionnaires. We also provide activity-based modules for specific disease indications including the 6-minute walk test, used by cardiovascular patient cohorts to avoid travel into clinic. We can also integrate devices and sensors, i.e. glucometers and spirometry. To enable self-management, we can provide in-app videos and digital leaflets for patient education. Equally important, patients have access to their dashboard, providing a visually engaging view of trends in their own health and wellbeing data.

Clinician dashboard
The Medopad platform is built specifically for each clinician and their patient cohort via a custom integration. Clinicians monitor and manage their patient cohort through a web-based dashboard, where they can view trends in patient data that otherwise were not available to them before. Empowered with increased information, stakeholders can create customised alerts to identify patients who are progressing poorly. By extension, data availability allows clinicians to provide a high level of personalisation in between clinic appointments by sending patients customised notifications to support self-management.

Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Mental Health: recovery, crisis and prevention / Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Education, training and future workforce / Wealth creation / Digital health / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
Medopad's solution enables clinicians to spot health deterioration sooner, preventing costly complications.  To name a few, we are working the Royal Free NHS Teaching Hospital, Guy's and St. Thomas's, Royal Salford, and Chelsea and Westminster.

At Guys' and St. Thomas' hospital, we are working with both community nurses and hospital vascular consultants to monitor venuous leg ulcer healing. While there are no estimates for the total cost burden of venous leg ulcers specifically, the total cost of acute and chronic wounds to the UK NHS is estimated to range from £4.5 to £5.1 billion, with 78% of costs falling on community NHS services for chronic wounds (Guest et al 2015). This pilot is currently underway. Patient's leg ulcers are photographed by themselves or the community nurse during wound dressing changes. Patients' acitivity is also tracked, as increasing mobility is a sign of a healing leg ulcer. This pilot is being used by vascular consultants to identify deteriorating wounds earlier, which may necessitate a move from a community-based management to hospital-based interventions. 

At the Royal Salford, we are working with consultants to monitor patients with renal disease. In this pilot, patients are completing tasks at home that would normally be done by the nurse. Specifically, patients are monitoring weight, blood pressure, and completing a urine test at home using Healthy IO's urine dip stick test. This saves the nures time when the patient does travel into clinic, where the nurse needs only complete the remaing blood test. Apart from saving nurses time during clinic, renal consultants are able to monitor patient progress in between appointments. If patients' blood pressure and weight are not deteriorating, the consultant may postpone the appointment, and equally, if indicators seem to be worsening, the consultant can provide timely care by bringing the patient in sooner. Renal disease is a costly condition; the NHS in England spent an estimated £1.45 billion on CKD in 2009–10. By monitoring patient progress, there is potential to reduce some of these costs by reducing disease progression and complications. 
Initial Review Rating
5.00 (1 ratings)
Benefit to WM population:
The Medopad platform provides clinicians with insight into patient progress in between clinic appointments, this has the potential to provide patients with preventative and timely care by spotting problems sooner (as described in the previous section). For the patient, prevention of further deterioration means improved quality of life. Additionally, the platform has the potential to reduce unnecessary clinic appointments for patients.

At the Royal Free, patients with peripheral arterial hypertension (PAH - a rare disease) are using the Medopad smartphone to avoid travelling into clinic for appointments. Instead, patients complete a six-minute walk test (a measure of disease progression) at home. Since it can be done from home, patients can do this more frequently, on a weekly basis, which provides clinicians with richer data on which to assess patient progress. Due to the nature of the condition, PAH patients suffer from symptoms like breathlessness that are made worse with activity. By avoiding long distance travelling to one of seven specialist PAH centres, patients' health is improved and they have a better experience of care. 

At the Harley Street Clinic, we have worked with children that have a rare form of brain cancer (DIPG). Parents recorded videos of their child performing certain tasks and recorded additional health data. The clinician was able to more frequently monitor the children's progress without putting additional undue strain on both parent and child. Using the platform in this way was particularly improtant for vulnerable patients, such as these children, not to mention reducing the burden on parents.  
Current and planned activity: 
As mentioned in the previous sections, our solution and deployments have been co-developed with clinical experts and innovators across several top UK NHS teaching hospitals. 

We are currently looking for partners in the West Midlands, such as the AHSN, clinicians, and nurses, to engage in several pilot projects across a range of disease areas. Medopad is offering pilot projects free of charge for 12 months as a way to gather evidence of effectiveness and cost-effectiveness for our solution. As a part of the project, we include implementation and ongoing support.

In the longer term, we are looking to provide a transformative experience of care by providing intelligent and AI-powered clinical support systems to move the needle from reactive to preventative care. In that vein, we are looking for motivated and committed health care professionals to work with us in this journey. 
What is the intellectual property status of your innovation?:
Medopad's IP is related to its smartphone app and clinician web-portal. 
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
Read more
Hide details
Innovation 'Elevator Pitch':
A medical screening technology based on a mathematical model of the autonomic nervous system & physiological systems which has significant potential to improve the cost-effectiveness of primary care
Overview of Innovation:
Strannik technology is based upon a mathematical model of the autonomic nervous system and physiological systems. It meets the key aims and objectives of the EC’s Human Brain Project: (i) to identify what the brain does and how it does it, (ii) to develop a new generation of cognitively-based screening technology, (iii) to understand and adapt with therapeutic effect the multi-level nature of brain function.  This is quite without precedent in modern medicine. The Strannik technology comprises Strannik Virtual Scanning (SVS) and Strannik Light Therapy (SLT). 
The technique can be viewed in a demonstration video at the following link:
SVS is a screening technology which has an unprecedented ability to determine the health of the patient i.e. it is able to determine 5-15 pathologies in each of the 30 main organs (including medical conditions for which the current tests are poor or for which there is currently an unmet clinical need), to differentiate between and quantify the extent of the genotype and phenotype in each pathology, and to determine the earliest onset of each pathology from its presymptomatic origins. The technique adopts a methodology more advanced than is currently used in most diagnostic technologies. It is non-invasive and more safe than contemporary diagnostic tests. The results are available in circa 20 minutes at a cost which is estimated to be 5-10 times lower than contemporary diagnostic tests. It presents the opportunity to screen the entire UK population once (or twice) each year for less than £5BN (est £3-4BN) and to reduce the cost of healthcare by an estimated £20BN pa.
(See Operating Manual:
The basic methodology, and the scope of this technology, is outlined in a series of 60 peer-reviewed medical papers.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Advanced diagnostics, genomics and precision medicine / Wellness and prevention of illness / Clinical trials and evidence / Digital health / Innovation and adoption / Person centred care
Benefit to NHS:
Strannik Virtual Scanning is able to determine all common pathologies in a single test of 20 minutes duration. In-market surveillance has indicated that SVS appears to be circa 2-23% more precise than contemporary methods of diagnosis. A recent non-clinical study in Spain (10/16) illustrated that the technology was able to determine all known medical conditions in the cohort of (20) patients.
Using the data derived from this cognitive, computer-based, test the technique determines the precise parameters of Strannik Light Therapy -which acts upon autonomic dysfunction, and (across a wide range of medical indications) appears to be typically 83-96% effective. This compares with the 50% effectiveness of drugs and also that the effectiveness of many drugs declines over a period.
  • reduce the flow of patients into the healthcare system;
  • reduce the cost and complexity of training the GP
  • improve the ability of the GP to identify complex medical conditions, reduce the need for repeat consultations, and/or avoid doctor errors
  • reduce the need for histopathology samples (nurses, rubber gloves, sampling tubes, transport costs, histopathology lab costs)
  • reduce expenditure in secondary care i.e. for highly expensive scans and tests;
  • provide health reports and increase the ability for patients to have a clear understanding of their health and assume responsibility for their health i.e. change the focus of medicine  from treating the symptoms to prevention
  • regularly screen the health of the most at-risk patients thereby reducing the need for A&E services
  • improve the accuracy of drug prescribing thereby avoiding mis-prescribing of drugs
  • reduce the need for drugs
  • reduce the overall cost of healthcare by an estimated £20BN pa
“I have to hand it to you. You have correctly and in precise detail identified the five or six major items which are known to be of concern to me”. Dr John Doran, Medical Director, Nottingham’s Queens Medical Center, November 2003.
Initial Review Rating
5.00 (1 ratings)
Benefit to WM population:
Support patients to obtain an early diagnosis to seek timely treatment.
Current and planned activity: 
Mimix Montague Healthcare is actively seeking NHS partnerships to move forward Strannik Technology. Evaluation and trials have been conducted in other countries (Russia and Spain) and a collaboration within the UK is currently being sought.
  • Procurement / Adoption of Strannick Technology within NHS Trusts
  • Evaluation / Validation / Clinical Trial - Need to gain additional validation seeking a trial centre.
  • Project Assistance required - The Company’s development project is interested in locating possible clinical / academic collaborators.
What is the intellectual property status of your innovation?:
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
3 years +
Ease of scalability: 
Regional Scalability:
The technology is immediately scaleable. In theory, and as an indication of scaleability, we could train 1000 practitioners to use Strannik technology within 4 weeks. 
Strannik Virtual Scanning is unique for a number of very good reasons e.g. (i) that it can determine pathological onset from its presymptomatic origins, (ii) it can determine the full spectrum of pathologies in all organs and not just a single biomarker, (iii) it can determine genotype and phenotype, and (iv) it can determine many conditions where there is currently an unmet clinical need.  Further studies are required to illustrate how such a sophisticated technology will complement the current range of biomarker tests which are generally used in clinical practice. The technique is non-invasive and has a base cost of circa £15/test thereby addressing safety and cost.  The procedure is entirely non-invasive which significantly enhances the patient experience, often experienced as 'a pleasure'.  
Strannik Light Therapy is based upon an understanding of how the brain regulates the autonomic nervous system.  A comparison of Strannik Light Therapy with contemporary methods of treating patients is likely to enhance the patient experience, result in significantly reduced side-effects, and will be at very much lower cost.
Success will be measured by reduced number of patient consultations, lower cost of diagnosing and treating patients. 
Adoption target:
Our aim is to secure the introduction of Strannik technology to every primary care practice
Rejection Reason:
Dear Mr Ewing Thank you very much for your submission to the Meridian Innovation Health Exchange. I can confirm that we have now reviewed your submission and i regret to inform you that we have not been able to identify any clinical champions for this project. While I appreciate that Strannick are looking for support on the evaluation/evidence side, feedback from clinical / academic colleagues has not been positive and therefore we have done everything possible to engage but the appetite isn't there unfortunately. Given that our network is not focussed in exploring this area at this time we will therefore close your idea leaving it visible to our Meridian users. We wish you luck with your innovation. Regards The Meridian Team
Read more
Hide details
Overview summary:
SMARTChip is a purine biosensor which uses a finger-prick sample of blood to detect ischaemic brain events that occur during a stroke. It’s been developed to address the need for a rapid diagnostic test to help decision making in early stages of a stroke.

SMARTChip was created by Prof Nick Dale of the University of Warwick and developed in a NIHR i4i research study carried out at UHCW NHS Foundation Trust under vascular surgeon Prof Chris Imray in collaboration with stroke physician Prof Christine Roffe of UHNM NHS Trust.
Challenge identified and actions taken :
Currently, patients suspected of a stroke are taken to A&E to have a CT scan as confirmation before given thrombolysis treatment; however, the length of time it takes to recognise stroke symptoms is critical as delay in treatment leads to increased damage to the brain. Furthermore, there are no diagnostic tests to help clinicians and paramedics to identify stroke, resulting in high levels of misdiagnosis and delays in treatment.

SMARTChip was created to reduce delays by diagnosing stroke faster and better informing clinical decision making.

Research proved that, at the onset of a stroke, the brain releases a detectable quantity of purines into the blood. Purines are produced and released by cells undergoing the oxidative stress that occurs during a stroke. SMARTChip measures these purines to detect and diagnose symptoms of a stroke faster, improving patient outcomes and saving the NHS time and money.

There were many practical challenges to overcome with the first proof-of-concept device developed (SMARTCap) including difficulty experienced by nurses accurately and rapidly collecting and measuring blood samples in test tubes. This led to modification of the design and the development of SMARTChip. SMARTChip only requires a finger-prick sample of blood thereby simplifying, miniaturising and speeding up the technology.
Impacts / outcomes: 

There are several positive outcomes from the SMARTChip project:
  • The study provided an excellent example of partnership working across academia, industry and the NHS.
  • The SMARTChip study has been featured in the national media with articles in The Guardian and the National Institute for Health Research Website.
  • The time it takes for SMARTChip to make a measurement is approximately 3-5 minutes.
  • SMARTChip will be used in conjunction with the existing assessment procedures such as FAST (Face, Arms, Speech, Time) and ROSIER (Rule Out Stroke in the Emergency Room) to aid clinicians to diagnose stroke more rapidly.
  • SMARTChip is also expected to help by triaging patients and directing them to the most appropriate clinical unit.
  • SMARTChip may also be able to detect a number of other injuries including traumatic brain injury (TBI), heart attack and foetal hypoxia.
  • SMARTChip has the potential to improve patient outcomes but also can save major cost to the NHS.
  • SMARTCHIP won the MidTECH Award for Best NHS-Developed Medical Technology Innovation at the WMHASN Awards 2018.
Which local or national clinical or policy priorities does this innovation address:
National Clinical Priority: One of the key priorities of the Stroke Association and the NHS RightCare Pathway is for stroke to have a more rapid diagnosis and treatment, from a 999 call through to optimal treatment. Every year, around 110,000 people in England have a stroke, and it is the third largest cause of death, after heart disease and cancer. Earlier diagnosis of stroke can better inform clinicians, meaning that treatment can be administered earlier. This leads to fewer complications later, as every minute that a major stroke is untreated, the brain loses some 1.9 million neurons, 14 billion synapses and 7.5 miles of myelinated fibres.
Supporting quote for the innovation from key stakeholders:
Quotes from Nicholas Dale, founder of Sarissa Biomedical Ltd:
“In 10 years’ time, I’d hope that SMARTChip will be in the defibrillator boxes that enable the public to treat cardiac arrest…upgraded with Sarissa’s SMARTChip, they should become multifunctional, enabling the public to contact the health service with more complete information.

“Sarissa has developed a world beating technology that will improve the lives of stroke victims and save the NHS money. Our ambition is to create jobs and economic wealth, we see the development of our production capability as being a key factor in transforming Sarissa from an R&D company into a high value IVD manufacturer and look forward to working with Aston University to deliver our ambition.”

Quote from Norman Phillips, Patient representative:
“Having had a stroke in 2003 at the age of 55 and being treated under the then current practice I was left with hemiplegia on the left side.

“After being discharged I took an interest in stroke treatment and research serving on many bodies and taking part in research in all areas.

“During the time since my stroke I have seen the introduction of the FAST campaign and fast tracking of patients to acute stroke units where diagnosing can be carried out, but, as we know, “time is brains.” The use of thrombolysis is governed by time so speed is of the essence.

“The introduction of SMARTChip will greatly reduce the time element and mean that treatment can begin sooner. Its use would also reduce the number of false diagnoses that turn out not to be a stroke.

“In my mind, and that of other stroke survivors and medical professionals that I have spoken to, this is a major breakthrough in the early diagnosis of the onset of a stroke.”
Plans for the future:
Further research studies using SMARTChip in an emergency setting will provide evidence for it to be implemented as an early diagnosis indicator of strokes. A planned study in an ambulance setting will also allow the device to be used and tested on patients with a suspected stroke before they arrive at A&E, again saving critical time in diagnosis and treatment.

Sarissa is now working on developing SMARTChip to support wider diagnosis and treatment of Ischemic Vascular Disease (IVD), with further trials planned for traumatic brain injury, heat attack, foetal hypoxia, limb ischaemia, peripheral artery disease and neurological disorders such as epilepsy.

In the longer term, a ‘wellness’ test is planned to screen people most at risk of a stroke and prevent them occurring.
Tips for adoption:
Final research and testing is reaching its conclusion, with an SBRI funded paramedic led trial of SMARTChip in the North West, North East and West Midlands NHS ambulance trusts and led by Dr Chris Price (Newcastle). SMARTChip is expected to achieve CE marking in 2020 with the product being available commercially by the start of 2021.
Contact for further information:
If you would like more information on the SMARTChip please contact:

Further information on Sarissa Biomedical Ltd and SMARTChip is available via the following links:
Read more
Hide details

Created by

Share and Follow